title: Conjunctival melanoma and melanocytic intra-epithelial neoplasia.
abstract: The rarity of conjunctival melanoma has impeded progress in the management of patients with this cancer; however, much progress has occurred in recent years. Primary acquired melanosis is now differentiated histologically into hypermelanosis and conjunctival melanocytic intra-epithelial neoplasia, for which an objective reproducible scoring system has been developed. Mapping and clinical staging of conjunctival disease has improved. Adjunctive radiotherapy and topical chemotherapy have made tumour control more successful, with reduced morbidity. Genetic analyses have identified BRAF and other mutations, which may predict responsiveness to new chemotherapeutic agents, for example Vemurafenib, should metastatic disease develop. Multicentre studies are under way to enhance survival prediction by integrating clinical stage of disease with histological grade of malignancy and genetic abnormalities. Such improved prognostication would not only be more relevant to individual patients, but would also provide greater opportunities for basic science research.
authors.affiliation: St Paul's Eye Unit, Liverpool Ocular Oncology Service, Royal Liverpool University Hospital, Liverpool, UK. nkenawy@liv.ac.uk
authors.forename: N
authors.initials: N
authors.lastname: Kenawy
authors.forename: S L
authors.initials: SL
authors.lastname: Lake
authors.forename: S E
authors.initials: SE
authors.lastname: Coupland
authors.forename: B E
authors.initials: BE
authors.lastname: Damato
mesh_terms: D003230:Conjunctival Neoplasms / Q000145:classification* / Q000235:genetics / Q000628:therapy; D003937:Diagnosis, Differential; D006801:Humans; D008545:Melanoma / Q000145:classification* / Q000235:genetics / Q000628:therapy; D009367:Neoplasm Staging; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics
chemical_list: C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf